Russell Investments Group’s Terns Pharmaceuticals TERN Stock Holding History

Russell Investments Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-244,898	Closed	-$12.9M	–	4521
2026 Q1	$12.9M	Sell	244,898 -2,129	-0.9%	-$87.4K	0.01%	797
2025 Q4	$9.98M	Buy	247,027 +214,855	+668%	+$4.97M	0.01%	911
2025 Q3	$242K	Buy	32,172 +7,352	+30%	+$46.9K	﹤0.01%	2741
2025 Q2	$92.6K	Sell	24,820 -3,368	-12%	-$10.5K	﹤0.01%	2838
2025 Q1	$77.8K	Sell	28,188 -600,207	-96%	-$2.45M	﹤0.01%	2807
2024 Q4	$3.48M	Sell	628,395 -116,292	-16%	-$787K	﹤0.01%	1360
2024 Q3	$6.21M	Buy	744,687 +96,571	+15%	+$795K	0.01%	1075
2024 Q2	$4.41M	Buy	648,116 +15,151	+2%	+$91.8K	0.01%	1207
2024 Q1	$4.15M	Buy	632,965 +355,224	+128%	+$2.32M	0.01%	1255
2023 Q4	$1.8M	Buy	+277,741	New	+$1.47M	﹤0.01%	1670

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Russell Investments Group's TERN Position: Q2 2026 in Review

Russell Investments Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 244,898 shares — an estimated $12.9M sold.

Russell Investments Group first reported a position in TERN in Q4 2023 and held it in 10 quarters. The position peaked at $12.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Russell Investments Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Russell Investments Group sold 244,898 Terns Pharmaceuticals shares in Q2 2026, an estimated $12.9M.
Russell Investments Group first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Russell Investments Group's Terns Pharmaceuticals position peaked at $12.9M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.